2025 second_quarter Filing

APOTEX CORP.forUnknown

Expenses

$300K

Method: A

Filed

July 18, 2025

View Original Document

Lobbying Activities

Health IssuesView all

Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; and Federal policy relating to the structure of the Department of Health and Human Services.

Contacted:HOUSE OF REPRESENTATIVES, SENATE, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), U.S. Trade Representative (USTR)

ManufacturingView all

Federal policy relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs.

Bureau of Industry and Security (BIS), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE

Lobbyists (1)

STEVEN GIULI